J Am Anim Hosp Assoc. 2021 Mar 1;57(2):81-90. doi: 10.5326/JAAHA-MS-7119.
The objective of this study was to provide preliminary data describing the safety and effect of cannabidiol (CBD) for symptom relief of canine osteoarthritis-associated pain in a clinical setting using objective outcome measures. Twenty-three client-owned dogs with naturally occurring osteoarthritis of appendicular joints completed this prospective, double-blinded, crossover, placebo-controlled study. Baseline data were acquired for 4 wk, followed by random allocation to either placebo or CBD treatment for 6 wk, followed by 6 wk with the opposite treatment. Outcome measures included objective gait analysis, activity counts (via accelerometry) and clinical metrology instruments. There were no differences noted between groups at any time point for any of the recorded outcome measures. Adverse events associated with CBD administration included elevation in liver enzymes (n = 14) and vomiting (n = 2).
本研究的目的是提供初步数据，描述使用客观结果测量在临床环境中使用大麻二酚 (CBD) 缓解犬骨关节炎相关疼痛的安全性和效果。23 只患有附肢关节自然发生骨关节炎的犬完成了这项前瞻性、双盲、交叉、安慰剂对照研究。在接受 4 周的基础数据采集后，随机分配给安慰剂或 CBD 治疗 6 周，然后再进行 6 周的相反治疗。结果测量包括客观步态分析、活动计数（通过加速度计）和临床计量学仪器。在任何时间点，记录的结果测量都没有显示两组之间有任何差异。与 CBD 给药相关的不良事件包括肝酶升高（n = 14）和呕吐（n = 2）。
